EU MDR and International Regulatory Divergence

Introduction

Healthcare bankers advising on cross-border MedTech transactions must understand that FDA clearance does not automatically translate to European market access, and vice versa. The EU Medical Device Regulation (MDR 2017/745), which became fully applicable in May 2021 (with extended transition periods), fundamentally changed the European regulatory landscape for medical devices, creating both risks and opportunities for MedTech companies and their acquirers.

The previous EU system (Medical Device Directives) relied on Notified Bodies to certify devices with relatively limited clinical evidence requirements. MDR significantly raised the bar:

Clinical evidence requirements. MDR requires substantially more clinical data than the previous directives, including clinical investigations (similar to clinical trials) for higher-risk devices. The previous system allowed many devices to rely on literature-based clinical evaluations and equivalence claims.

Post-market surveillance. MDR mandates active post-market clinical follow-up (PMCF) for most device classes, periodic safety update reports (PSURs), and a new European database for medical devices (EUDAMED) for transparency and traceability.

Unique Device Identification (UDI). All devices must carry a unique identifier enabling traceability from manufacturer through the supply chain to the patient.

Notified Body

An independent organization designated by an EU member state to assess whether medical devices meet MDR requirements before they can receive a CE mark and be sold in Europe. Unlike the FDA (a single government agency), the EU system relies on multiple private Notified Bodies competing for manufacturer business. MDR's stricter designation requirements reduced the number of active Notified Bodies from approximately 96 under the previous MDD directive to approximately 50 under MDR, creating capacity constraints and certification backlogs.

The MDR transition has created significant disruption:

Portfolio attrition. Some manufacturers have withdrawn lower-volume or older devices from the European market rather than invest in MDR recertification. Industry estimates suggest 10-30% of previously CE-marked devices may not be recertified under MDR, reducing product availability for European healthcare providers.

Certification backlogs. Fewer Notified Bodies combined with more rigorous review requirements have created 12-24 month certification backlogs. Companies planning European product launches must account for these delays in their financial models.

Cost increases. MDR compliance costs (clinical investigations, PMCF, UDI implementation, Notified Body fees) have increased regulatory spending for European market access by an estimated 30-50% compared to the previous directive system.

The European Commission recognized the MDR transition challenges and proposed simplification measures in December 2025 to reduce burden while maintaining safety standards. Key proposals include streamlined procedures for certain device modifications, extended transition timelines for legacy devices, and reduced documentation requirements for lower-risk devices. These proposals are still under legislative review, creating uncertainty about the final framework.

This article concludes the Medical Devices & MedTech section. The next section covers Healthcare Services, where the business model shifts from physical products to labor-intensive service delivery and the fragmentation thesis drives PE-led consolidation.